Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention

Andrew J. Dannenberg, Scott M. Lippman, Jason R. Mann, Kotha Subbaramaiah, Raymond N. DuBois

    Research output: Contribution to journalReview articlepeer-review

    319 Scopus citations

    Abstract

    Understanding the mechanisms underlying carcinogenesis provides insights that are necessary for the development of therapeutic strategies to prevent cancer. Chemoprevention, the use of drugs or natural substances to inhibit carcinogenesis, is a rapidly evolving aspect of cancer research. Evidence is presented that cyclooxygenase-2 (COX-2) and epidermal growth factor receptor (EGFR) are potential pharmacologic targets to prevent cancer. In this paper, we review key data implicating a causal relationship between COX-2, EGFR, and carcinogenesis and possible mechanisms of action. We discuss evidence of crosstalk between COX-2 and EGFR in order to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial that will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.

    Original languageEnglish (US)
    Pages (from-to)254-266
    Number of pages13
    JournalJournal of Clinical Oncology
    Volume23
    Issue number2
    DOIs
    StatePublished - 2005

    ASJC Scopus subject areas

    • Oncology
    • Cancer Research

    Fingerprint Dive into the research topics of 'Cyclooxygenase-2 and epidermal growth factor receptor: Pharmacologic targets for chemoprevention'. Together they form a unique fingerprint.

    Cite this